Mesa Laboratories, Inc. (MLAB) designs and manufactures life sciences tools and critical quality control solutions used in regulated applications across the pharmaceutical, healthcare, and medical device industries. Unlike many healthcare names, Mesa is not a drug developer or a device maker focused on a single product. Instead, it supplies the instruments, consumables, and testing services that other companies rely on to prove their products are sterile, safe, accurately measured, and compliant with strict regulations. That positioning—supporting the quality and safety infrastructure of regulated industries—is the core of the company's business model and a key reason investors follow the stock.
Mesa Laboratories was incorporated in 1982 and is headquartered in Lakewood, Colorado, with manufacturing operations in the United States and Europe and commercial reach across North America, Europe, and the Asia-Pacific region. The company's fiscal year ends on March 31. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Mesa reports its operations across four business segments:
The business model emphasizes recurring revenue. A large portion of Mesa's sales comes from consumables, reagents, indicators, and testing services that customers must repeatedly purchase to remain compliant and keep their instruments running—often for years after the initial hardware sale. This creates a relatively stable financial profile, reflected in the company's historically high gross margins.
Mesa Laboratories attracts investor attention primarily because of its exposure to durable, regulation-driven demand. In heavily regulated fields such as drug manufacturing and healthcare, quality control testing is not optional; it is a legal and safety requirement. That makes demand for Mesa's products less discretionary than in many other industrial or technology businesses.
The company also benefits from a diversified revenue base across four distinct segments, which reduces reliance on any single market. Its Sterilization and Disinfection Control and Calibration Solutions businesses provide steady, compliance-oriented demand, while its Biopharmaceutical Development and Clinical Genomics segments offer exposure to long-term growth themes in biologic drug development and genetic testing. Additionally, Mesa has historically grown through acquisitions, integrating niche quality-control businesses into its platform—an approach that supports both product breadth and market position.
Investors should weigh several factors before considering MLAB. Customer concentration is a notable concern: a single customer has historically accounted for a meaningful portion of Clinical Genomics revenue. The company also faces geopolitical and trade-related risks, particularly around tariffs and export controls that have affected its China sales and Biopharmaceutical Development shipments.
Other considerations include foreign currency exposure, which can affect reported results, and reliance on sole or limited sources for certain materials. As an acquisition-driven company, Mesa also carries integration risk and has at times recorded significant non-cash impairment charges. Finally, its operations are subject to evolving regulatory requirements, including cybersecurity rules and U.S. Food and Drug Administration (FDA) standards, which can raise compliance costs.
Mesa Laboratories occupies a distinctive niche as a provider of critical quality control tools and consumables for regulated life sciences and healthcare markets. Its four-segment structure, recurring-revenue orientation, and embedded role in compliance workflows distinguish it from more volatile product-focused companies. At the same time, its exposure to customer concentration, trade dynamics, and acquisition-related risks means its performance can vary across cycles. For investors seeking to understand a diversified, regulation-driven life sciences tools business, MLAB offers a useful case study in how recurring consumables and quality-control demand underpin a specialized market position.
In my research process, I often turn to Tickeron’s AI Screener to quickly filter through stocks based on criteria like industry, fundamentals, and AI signals. It’s been helpful for comparing companies like Mesa Laboratories to peers in the life sciences space and identifying patterns that align with my own strategies.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MLAB broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 34 of the 40 cases the stock fell afterwards. This puts the odds of success at 85%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for MLAB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on MLAB as a result. In 69 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for MLAB just turned positive on November 10, 2026. Looking at past instances where MLAB's MACD turned positive, the stock continued to rise in 45 of 53 cases over the following month. The odds of a continued upward trend are 85%.
MLAB moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MLAB crossed bullishly above the 50-day moving average on November 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 86%.
Following a +8.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLAB advanced for three days, in 224 of 307 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. MLAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.802) is normal, around the industry mean (1.448). MLAB has a moderately high P/E Ratio (150.882) as compared to the industry average of (5.350). Projected Growth (PEG Ratio) (1.390) is also within normal values, averaging (5.470). Dividend Yield (0.005) settles around the average of (0.012) among similar stocks. P/S Ratio (2.818) is also within normal values, averaging (32.028).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of computer-based electronic measurement instruments
Industry ElectronicEquipmentInstruments